@inbook{3b92c593329d45fc8b4a5f8ee67a0a99,
title = "CHAPTER 7: Traditional Cytotoxic Agents as Antibody-Drug Conjugate (ADC) Payloads",
abstract = "Although the concept of antibody-drug conjugates (ADCs) appears simple, the development of successful and efficacious agents has proved challenging. For example, many parameters have to be optimized to create a successful ADC product, some of which are specific to individual tumour types and antibodies. Important parameters include ADC stability (e.g. the payload should not be released before the ADC reaches its target in vivo), pharmacokinetics (e.g. the payload should not lead to undesired accumulation in a non-target organ), retention of immuno-reactivity, and efficient release of the active form of the payload at the disease site. Early work on ADCs relied on clinically-approved chemotherapeutic drugs as payloads with the aim of increasing tumour specificity.",
author = "Ilona Pysz and Paolo Andriollo and Thurston, {David E.}",
year = "2019",
month = jan,
day = "1",
doi = "10.1039/9781788012898-00137",
language = "English",
series = "RSC Drug Discovery Series",
publisher = "Royal Society of Chemistry",
number = "71",
pages = "137--165",
editor = "Thurston, {David E.} and Jackson, {Paul J. M.}",
booktitle = "Therapies for Retinal Degeneration",
address = "United Kingdom",
edition = "71",
}